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ABSTRACT
ObjeCtives
To provide contemporary estimates of the prevalence 
of microcephaly in Europe, determine if the diagnosis 
of microcephaly is consistent across Europe, and 
evaluate whether changes in prevalence would be 
detected using the current European surveillance 
performed by EUROCAT (the European Surveillance of 
Congenital Anomalies).
Design
Questionnaire and population based observational 
study.
setting
24 EUROCAT registries covering 570 000 births 
annually in 15 countries.
PartiCiPants
Cases of microcephaly not associated with a genetic 
condition among live births, fetal deaths from 20 
weeks’ gestation, and terminations of pregnancy for 
fetal anomaly at any gestation.
Main OutCOMe Measures
Prevalence of microcephaly (1 Jan 2003-31 Dec 2012) 
analysed with random effects Poisson regression 
models to account for heterogeneity across registries.
results
16 registries responded to the questionnaire, of which 
44% (7/16) used the EUROCAT definition of 
microcephaly (a reduction in the size of the brain with 
a skull circumference more than 3 SD below the mean 
for sex, age, and ethnic origin), 19% (3/16) used a 2 SD 
cut off, 31% (5/16) were reliant on the criteria used by 
individual clinicians, and one changed criteria 
between 2003 and 2012. Prevalence of microcephaly in 
Europe was 1.53 (95% confidence interval 1.16 to 1.96) 
per 10 000 births, with registries varying from 0.4 (0.2 
to 0.7) to 4.3 (3.6 to 5.0) per 10 000 (χ2=338, df=23, 
I2=93%). Registries with a 3 SD cut off reported a 
prevalence of 1.74 per 10 000 (0.86 to 2.93) compared 
with those with the less stringent 2 SD cut off of 1.21 
per 10 000 (0.21 to 2.93). The prevalence of 
microcephaly would need to increase in one year by 
over 35% in Europe or by over 300% in a single registry 
to reach statistical significance (P<0.01).
COnClusiOns
EUROCAT could detect increases in the prevalence of 
microcephaly from the Zika virus of a similar 
magnitude to those observed in Brazil. Because of the 
rarity of microcephaly and discrepant diagnostic 
criteria, however, the smaller increases expected in 
Europe would probably not be detected. Clear 
diagnostic criteria for microcephaly must be adopted 
across Europe.
Introduction
Microcephaly is a congenital anomaly where a baby’s 
head is smaller compared with other babies of the same 
sex, age, and ethnicity. The definition of “smaller” var-
ies from a head circumference more than 2 SD below the 
mean to more than 3 SD below the mean. The more 
extreme the definition of “smaller” the greater the pro-
portion of babies diagnosed with microcephaly who 
will have smaller underdeveloped brains and who are 
consequently at risk of developmental delay, intellec-
tual disability, and physical disabilities such as hearing 
and vision impairment.1  In a cohort of 680 children 
with microcephaly the aetiology was genetic in 31%, 
perinatal brain injuries in 27% (including maternal 
exposure to teratogens in 4%), postnatal brain injuries 
in 2%, and unknown in 41%.2
In late 2015, there were reports of a dramatic increase 
in the prevalence of microcephaly in Brazil, coinciding 
with an outbreak of the Zika virus several months ear-
lier.3  There is now sufficient evidence to confirm that 
infection with the Zika virus during the first trimester of 
pregnancy increases the risk of microcephaly in the 
baby.4 5 The emerging microcephaly epidemic across 
South America has highlighted the necessity of accu-
rate congenital anomaly surveillance.
We carried out a population based study to provide 
contemporary estimates of the prevalence of 
WhAT IS AlReAdy knoWn on ThIS TopIC
Maternal infection with Zika virus during the first trimester of pregnancy increases 
the risk of microcephaly in the baby
In South America clinicians noticed a dramatic increase in the prevalence of 
microcephaly, which was confirmed by surveillance
European surveillance of congenital anomalies is performed by EUROCAT (the 
European Surveillance of Congenital Anomalies; www.eurocat-network.eu/)
WhAT ThIS STudy AddS
The reported prevalence of microcephaly across Europe varies considerably 
because of the different diagnostic criteria applied and varying levels of 
ascertainment
EUROCAT could detect increases in the prevalence of microcephaly due to the Zika 
virus of a similar magnitude to those observed in Brazil
Because Aedes mosquitoes are not indigenous in most of Europe, associated 
increases in the prevalence of microcephaly would probably be smaller and unlikely 
to be detected
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 microcephaly in Europe, determine if the diagnosis of 
microcephaly is consistent across Europe, and evaluate 
whether changes in prevalence would be detected with 
the current European surveillance performed by EURO-
CAT (the European Surveillance of Congenital Anoma-
lies; www.eurocat-network.eu/).
Methods
EUROCAT is a European network of almost all popula-
tion based registries of congenital anomaly in Europe 
and currently provides the most complete information 
on congenital anomalies occurring in the area. EURO-
CAT was established in 1979, and there are currently 43 
registries in 23 countries covering more than 29% of 
European births (1.7 million) each year. The European 
Union has provided funding for a central registry to 
coordinate the network, and the member registries are 
funded locally by national or regional governments, 
research, or other bodies. All EUROCAT registries have 
a defined geographical coverage (a map for registries 
included in EUROCAT can be found at www.euro-
cat-network.eu/content/EUROCAT-Population-Ta-
ble-I-Year2012.pdf); in some countries all births are 
covered by a registry (such as in Hungary, Malta, Nor-
way, Poland, and Sweden) and in some countries less 
than 10% are covered by a registry (such as in Germany, 
the Netherlands, and Ukraine).
All EUROCAT registries use multiple sources of infor-
mation to ascertain cases among all live births, late fetal 
deaths (>20 weeks’ gestation), and terminations of preg-
nancy for fetal anomaly at any gestation.6  Data sources, 
depending on registry, include maternity, neonatal, and 
paediatric records; fetal medicine, cytogenetic, pathol-
ogy, and medical genetics records; specialist services 
including paediatric cardiology; and hospital discharge 
and child health records. The EUROCAT central data-
base is hosted by the European Commission Joint 
Research Centre in Ispra, Italy, since 2015. Registries 
either submit individual anonymised records of cases of 
congenital anomalies (full members) or submit the same 
data in aggregate form (associate members). All cases 
are coded with ICD-9 or ICD-10 (international classifica-
tion of diseases, ninth or 10th versions) with 1-digit Brit-
ish Paediatric Association (BPA) extension. In each case 
there can be one syndrome and up to eight malforma-
tion codes. All coding is standardised by using the 
EUROCAT guide (version 1.4) with isolated minor anom-
alies, such as skin tags, being excluded.7
A set of 30 data quality indicators is used to assess 
five key elements of data quality: completeness of case 
ascertainment, accuracy of diagnosis, completeness of 
information on EUROCAT variables, timeliness of data 
transmission, and availability of population denomina-
tor information.8  Surveillance and research are per-
formed with data only from registries with sufficiently 
high data quality. For inclusion in the annual monitor-
ing of trends, registries must not be more than a year 
behind in data transmission and have provided data for 
at least nine of the previous 10 years.9  Twenty five reg-
istries satisfied these criteria for 1 January 2003 to 31 
December 2012.10
In EUROCAT’s annual monitoring of trends for con-
genital anomalies excluding genetic conditions, all 
cases with a chromosomal anomaly, genetic syn-
drome, microdeletion, or skeletal dysplasia are 
excluded for two reasons. Firstly, registries differ in 
their reporting of associated anomalies in cases with a 
genetic condition, and, secondly, these genetic condi-
tions are aetiologically different from other anomalies. 
For example, over 10% of infants with Patau syndrome 
have microcephaly11 and the risk of a pregnancy with 
Patau syndrome increases with maternal age. There-
fore, if mean maternal age increases in a population, 
there would be more cases of Patau syndrome and 
hence also more cases of microcephaly. This increase 
in microcephaly could mask other important trends 
from changes in the exposure to teratogens. Known 
genetic conditions are well recorded as most registries 
receive information directly from cytogenetic laborato-
ries, as indicated by a specific data quality indicator 
assessing ascertainment of Down’s syndrome. In April 
2014, the EUROCAT central registry held at Ulster Uni-
versity extracted aggregate data on all cases of micro-
cephaly excluding genetic conditions from 1 Jan 1980 
to 31 Dec 2012.
The EUROCAT definition of microcephaly is “a reduc-
tion in the size of the brain with a skull circumference 
more than 3 SD below the mean for sex, age and ethnic 
origin.”7 Many registries, however, receive the diagnosis 
of microcephaly from a clinician and might not be able 
to ensure that the EUROCAT definition is used. To find 
out whether this was the case, we sent a questionnaire 
to all EUROCAT registries with the following questions:
•	 Do you have a strict definition of microcephaly?
•	 Do you use the EUROCAT definition?
•	 Do you use growth charts for defining microcephaly?
•	 Do you report the cases that the clinicians report to 
you  or do you assess the diagnosis within your 
 registry?
We fitted a Poisson random effects model to estimate 
the European prevalence of microcephaly from 2003 to 
2012 and examined the degree of heterogeneity using 
the I2 test statistic.9 10 We used a Poisson model as these 
models are used to predict the number of times a rare 
event (in this case microcephaly) will occur when many 
general events occur (in this case all pregnancies). A 
random effects model assumes that the true prevalence 
of microcephaly in each registry will vary. Poisson 
regression models were fitted for the number of micro-
cephaly cases diagnosed each year with the total num-
ber of births in the population each year as the exposure 
variable to examine linear trends in the years from 2003 
to 2012 for each registry separately. Multilevel Poisson 
regression models were also fitted with the data from 
1980 to 2012, with data from each two yearly interval 
combined and entered as a categorical variable and 
each registry as a stratum to estimate a registry adjusted 
two yearly prevalence of microcephaly. We chose two 
years to reduce the random fluctuations present in the 
data. All analyses were performed with Stata software 
version 12.
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Patient involvement
As this study is part of EUROCAT’s routine surveillance 
of congenital anomalies no patients were involved in 
setting the research question or the outcome measures, 
nor were they involved in developing plans for imple-
mentation of the study. No patients were asked to advise 
on the interpretation or writing up of results. There are 
no plans to disseminate the results of the research to 
study participants. However, the results will be avail-
able on the EUROCAT website.
Results
Sixteen of the 25 participating registries (64%) replied 
to the EUROCAT microcephaly questionnaire. In 2006 
one registry changed their diagnostic criteria for micro-
cephaly from below the 10th centile to below the 3rd 
centile so it was therefore excluded from the data anal-
ysis. Seven (44%) registers used the 3 SD cut off 
 recommended by EUROCAT, three (19%) used a 2 SD cut 
off, and the remaining five (31%) registers relied on the 
criteria used by individual clinicians. Most registries 
used country specific growth charts, with one registry 
using the WHO 2006 Child Growth Standard.12
Table 1  shows the considerable variations in birth 
population surveyed by the 24 registries, with the larg-
est registry covering almost 100 000 births a year and 
the smallest only 3500. Microcephaly is a rare congeni-
tal anomaly and hence only two registries (8%) 
recorded an average of more than 10 cases a year, and 15 
registries (63%) had at least one year from 2003 to 2012 
during which they did not record a single case. In total, 
there were 570 000 births resulting in 100 cases of 
microcephaly a year. Figure 1 shows the changes in the 
biennial prevalence (adjusted for registry) from 1980 to 
2012. The small number of cases per year means that 
large changes in prevalence will occur due to chance, 
such as the 37% increase in European prevalence from 
1992 to 1994.
The estimated prevalence of microcephaly in Europe 
from 2003 to 2012 was 1.53 (95% confidence interval 1.16 
to 1.96) per 10 000 births (fig 2). There was considerable 
heterogeneity between registries (χ2=338, df=23, 
I2=93%). There was no indication that registries that 
used more stringent diagnostic criteria had a lower 
prevalence than those with less stringent criteria: seven 
registries that used the 3 SD cut off reported a preva-
lence of 1.74 per 10 000 (95% confidence interval 0.86 to 
2.93), three registries that used a 2 SD cut off reported a 
prevalence of 1.21 per 10 000 (0.21 to 2.93), and five reg-
istries that relied on the criteria used by individual cli-
nicians reported a prevalence of 1.81 per 10 000 (0.29 to 
4.57).
For the 10 years from 2003 to 2012, there was an aver-
age annual decrease in the prevalence of microcephaly 
of 2% (95% confidence interval −4% to 0%) a year 
(table 1). There was considerable heterogeneity between 
registries for this trend in prevalence (χ2=79.29, df=23, 
I2=71%).10
discussion
The prevalence of microcephaly across Europe varies 
considerably, probably due to a combination of three 
different factors: the diagnostic criteria and how they 
are applied; the different levels of ascertainment 
table 1 | numbers of microcephaly cases (excluding genetic conditions) according to eurOCat registry since 1980
registry 1st year
Final 
year
no of 
years 
of data
average no 
of cases/year
average no of 
births/year
no of years 
with no cases 
2003-12
no of cases/10 000 
births 2003-12 (95% Ci)
annual % change in 
prevalence 2003-12 
(95% Ci)
Hungary 1998 2011 14 15.3 96 297 0 1.8 (1.6 to 2.1) 2 (−4 to 8)
UK, East Midlands and South Yorkshire 1998 2012 15 8.5 66 577 0 1.0 (0.8 to 1.3) −6 (−13 to 2)
Norway 1999 2012 14 2.7 59 753 1 0.5 (0.3 to 0.7) −2 (−14 to 12)
UK, Wales 1998 2012 15 15.8 33 448 0 4.3 (3.6 to 5.0) −11 (−16 to −6)
France, Paris 1981 2012 32 8.0 33 044 0 2.9 (2.3 to 3.6) 8 (0 to 17)
UK, Northern England 2000 2012 13 4.5 32 056 1 1.3 (0.9 to 1.7) −17 (−26 to −7)
Italy, Emilia Romagna 1981 2012 32 3.4 28 484 1 1.2 (0.9 to 1.6) 13 (1 to 26)
UK, Wessex 1994 2012 19 2.3 27 599 0 0.8 (0.6 to 1.2) −11 (−23 to 3)
Ireland, Dublin 1980 2012 33 6.3 22 521 0 2.2 (1.7 to 2.9) −18 (−26 to −10)
Italy, Tuscany 1980 2012 33 1.8 20 809 0 0.7 (0.4 to 1.0) −9 (−23 to 6)
Spain, Basque Country 1990 2011 22 3.6 18 155 0 2.9 (2.2 to 3.8) 11 (0 to 23)
Netherlands, North 1981 2012 32 3.8 16 581 1 1.7 (1.2 to 2.4) 16 (1 to 32)
Belgium, Antwerp 1990 2012 23 4.0 15 778 1 2.3 (1.7 to 3.1) −3 (−13 to 7)
Portugal, South 1990 2011 22 1.8 15 432 5 0.4 (0.2 to 0.8) 0 (−17 to 19)
UK, Thames Valley 1991 2012 22 1.1 14 679 1 0.9 (0.6 to 1.4) −1 (−8 to 6)
France, Isle de Reunion 2002 2012 11 4.6 14 596 0 3.2 (2.4 to 4.3) 22 (9 to 36)
Belgium, Hainaut 1980 2012 33 2.6 11 465 1 1.5 (1.0 to 2.3) −4 (−13 to 5)
Ireland, Cork and Kerry 1996 2012 17 2.1 8907 5 0.9 (0.5 to 1.8) −3 (−15 to 12)
Switzerland, Vaud 1989 2012 24 1.5 7600 2 1.7 (1.0 to 2.9) 1 (−12 to 16)
Ireland, South East 1997 2012 16 2.1 6796 3 2.3 (1.4 to 3.7) −12 (−26 to 4)
Croatia, Zagreb 1983 2012 30 1.7 6367 6 0.6 (0.2 to 1.5) 4 (−9 to 18)
Denmark, Odense 1980 2012 33 1.0 5272 6 1.0 (0.4 to 2.3) −7 (−20 to 9)
Malta 1986 2011 26 1.2 4619 1 3.0 (1.7 to 5.4) 3 (−9 to 17)
Germany, Mainz 1990 2011 22 0.4 3425 6 1.4 (0.5 to 3.6) 1 (−15 to 21)
European estimate — — — 100.1 570 260 — 1.53 (1.16 to 1.96) −2 (−4 to 0)
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( registries with active ascertainment procedures show a 
higher prevalence than registries with more passive 
procedures); and the application of growth curves to 
populations with different ethnic backgrounds.
The prevalence reported here excluded all cases with 
a genetic condition (a chromosomal anomaly, genetic 
syndrome, microdeletion, or skeletal dysplasia). In 
EUROCAT a genetic condition was recorded in an addi-
tional 23% of microcephaly cases. This is lower than the 
31% of cases with a genetic condition observed in a 
study on the aetiology of microcephaly in 680 children.2 
This could be because some registries do not include all 
associated anomalies in cases with a genetic condi-
tion.11  Inflation of the observed prevalence of micro-
cephaly in this study by 31% gives an estimated 
prevalence of microcephaly including genetic condi-
tions of 2.0 per 10 000 (95% confidence interval 1.53 to 
1.31). This compares with reported prevalences, includ-
ing genetic conditions, of 1.98 per 10 000 (1.48 to 2.27) 
by ECLAMC in Brazil (before the Zika virus epidemic),13 
2.3 per 10 000 (1.82 to 2.78) in India,14  and 6.0 per 10 000 
(4.5 to 7.7) in the US.15
Around 100 cases of microcephaly occur each year 
(table 1). As the occurrence of cases has an approximate 
Poisson distribution, if the number of births does not 
change significantly there would have to be an increase 
of over 35% of cases in a year for this to be identified as 
a significant increase at P<0.01 (100 v 135 is P=0.009). 
The average number of cases per registry per year is four 
(table 1), and hence the equivalent increase in preva-
lence would be over 300% in a single registry to reach 
significance (4 v 13; P=0.006). If multiple comparisons 
were adjusted for, such increases would need to be 
greater. EUROCAT annual statistical monitoring also 
uses scan statistic methods within registries, and this 
would also require an increase of over 300% to be likely 
to be detected.16
In Brazil, the increase in reporting of microcephaly 
by the Live Birth Information System (Sistema de Infor-
mações sobre Nascidos Vivos, SINASC) was about four-
fold in the country as a whole, with the prevalence in 
the north east rising 10-fold, though these increases 
were partly influenced by improved ascertainment.13 17 
As calculated above, the EUROCAT surveillance system 
would have detected increases of this magnitude. 
Future increases in prevalence of microcephaly in 
Europe due to the Zika virus, however, would be 
expected to be considerably smaller than those that 
have occurred in South America because Aedes mosqui-
toes are not indigenous in Europe. Such changes in 
prevalence would therefore be unlikely to be detected 
through routine surveillance. Maternal exposure to the 
Zika virus, however, should be considered for any 
newly diagnosed microcephaly cases.
strengths and weaknesses
The strength of this study is that the EUROCAT registries 
are population based and cover 600 000 births annu-
ally in 15 countries. In addition, all cases are included, 
not just those in infants who are receiving treatment at 
specialist hospitals. A limitation of EUROCAT is that the 
definition of microcephaly is, for many registries, at the 
discretion of the patient’s clinician. This means that 
standardising diagnostic criteria can be difficult. There 
are clear discrepancies in the application of the diag-
nostic guidelines as if head circumference had a Gauss-
ian (normal) distribution we would expect the head 
circumference in 0.13% of babies to be more than 3 SD 
below the mean and in 2.3% to be more than 2 SD below 
the mean (prevalences of around 13 per 10 000 to 230 
per 10 000), which is inconsistent with the observed 
prevalences from Europe, Brazil, India, and the US.14 15 17 
In the case of microcephaly, collection of additional 
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information such as the gestational age of the baby at 
birth, the age of the baby at the time of diagnosis of 
microcephaly, the head circumference of the child, and 
the ethnic group of the child would enable EUROCAT to 
more accurately determine discrepancies in diagnosis 
and also to ensure more consistent diagnostic criteria.
The recent (4 March 2016) WHO interim guidelines for 
diagnosing microcephaly are: “Neonates with a head 
circumference more than 2 standard deviations below 
the mean are considered to have microcephaly. Neo-
nates with a head circumference more than 3 standard 
deviations below the mean should be considered to 
have severe microcephaly.”18  Implementation of this 
new definition will greatly increase the prevalence of 
microcephaly, with potentially an additional 2.2% 
(2.3%−0.1%) of babies having a diagnosis of microceph-
aly. This will result in a much greater proportion of 
babies labelled as microcephalic who will have no 
detectable neurological impairment.1  The feasibility of 
such a change requires further assessment. The appli-
cation of the WHO definition has other limitations in 
Europe. The WHO has a set of tables with head circum-
ference for term neonates12  and recommends the use of 
Intergrowth standards for preterm neonates.19  Studies 
from Norway, Belgium, and the UK, however, have 
found that the WHO tables are not accurate for the chil-
dren in their cohorts20 21; these children had larger 
heads, which would result in the underdiagnosis of 
microcephaly. Similarly, these tables might not be suit-
able for children from other ethnic groups that have 
smaller heads on average.
Conclusions
The emergence of the Zika virus and its association with 
microcephaly highlights the necessity for a more stan-
dardised application of agreed diagnostic criteria. It 
also emphasises the necessity of continued surveillance 
of all congenital anomalies within each country in 
Europe. Potential teratogens are often identified by 
alert clinicians (such as in the case of thalidomide). 
Congenital anomaly registries with accurate baseline 
data are then essential to evaluate the true severity of 
any new epidemic. For rare diseases, the pooling of 
standardised data across Europe by EUROCAT to obtain 
accurate baseline data is essential to detect and evalu-
ate any future environmental teratogens in a timely 
manner.
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